1-硫代-β-D-葡萄糖钠 | 10593-29-0

• 物质功能分类: 生物化工 - 糖类化合物 - 单糖
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-硫代-β-D-葡萄糖钠
• 中文别名: Β-D-硫代葡萄糖钠盐；1-硫代-beta-d-葡萄糖钠
• 英文名称: 1-Thio--D-glucose sodium salt
• CAS: 10593-29-0
• 化学式: C6H12NaO5S
• 分子量: 219.21
• InChiKey: BHHKGFGJKMSQDZ-WNFIKIDCSA-N

物化性质

• 熔点：
  173°C
• 溶解度：
  水（轻微）、甲醇（非常轻微、加热、超声处理）

计算性质

• 辛醇/水分配系数(LogP)：
  -2.66
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  91.2
• 氢给体数：
  5
• 氢受体数：
  6

安全信息

• 安全说明：
  S24/25,S6
• WGK Germany：
  3
• 海关编码：
  29329990
• 危险品运输编号：
  NONH for all modes of transport

文献信息

• Novel methods for the delivery of polynucleotides to cells
  申请人：——

  公开号：US20030235916A1

  公开（公告）日：2003-12-25

  Process are described for the delivery of a polynucleotide to a cell. The process comprises forming a salt stable complex between the polynucleotide and a cationic surfactant. Ternary complexes are also made by associating an amphipathic compound with the binary complex. The resultant complexes are suitable for delivery of the polynucleotide to cells in vitro and in vivo.

  描述了将多核苷酸传递到细胞的过程。该过程包括在多核苷酸和阳离子表面活性剂之间形成一个盐稳定的复合物。三元复合物也可以通过将一个两性化合物与二元复合物结合而制备。所得的复合物适用于体外和体内向细胞传递多核苷酸。
• APPLICATION OF METAL COMPLEXES IN ANTI-TUMOR AND ANTI-BACTERIAL THERAPY
  申请人：biolitec Unternehmensbeteiligungs II AG

  公开号：US20190241593A1

  公开（公告）日：2019-08-08

  The present invention provides biologically active compounds and methods to obtain biologically active compounds that can be used as photosensitizers for diagnostic and therapeutic applications, particularly for PDT of cancer, infections and other hyperproliferative diseases, fluorescence diagnosis and PDT treatment of non-tumorous indications such as arthritis, inflammatory diseases, viral or bacterial infections, dermatological, ophthalmological or urological disorders. As the compounds exhibit also toxicity against targets (tumor cells, bacteria, inflammation-related cells) without light these biologically active compounds may also be used for the light-independent treatment of such indications. Preferred embodiments of the present invention consist of methods to synthesize metal or half-metal complex structures incorporating one or more substituted 2,3,5,6-tetrafluorophenyl-dipyrromethene (2,3,5,6-tetrafluorophenyldipyrrin) units. These dipyrromethenes (dipyrrins) can carry a variety of different substituents in the 4-position enabling a fine tuning of their biological or amphiphilic/hydrophilic properties. Another object of the present invention is to provide amphiphilic compounds with a higher membrane affinity and increased efficacy.

  本发明提供了生物活性化合物和获得这些生物活性化合物的方法，这些化合物可用作诊断和治疗应用的光敏剂，特别是用于癌症、感染和其他过度增殖疾病的光动力疗法（PDT），以及用于非肿瘤指示物的荧光诊断和PDT治疗，如关节炎、炎症性疾病、病毒或细菌感染、皮肤科、眼科或泌尿学障碍。由于这些化合物对靶标（肿瘤细胞、细菌、与炎症相关的细胞）也表现出毒性，因此这些生物活性化合物也可用于对这些指示物进行独立于光的治疗。本发明的优选实施例包括合成金属或半金属配合物结构的方法，其中包含一个或多个取代的2,3,5,6-四氟苯基二吡咯甲烷（2,3,5,6-四氟苯基二吡咯）单元。这些二吡咯甲烷（二吡咯）在4-位可以携带各种不同的取代基，从而微调它们的生物性质或两性/亲水性质。本发明的另一个目的是提供具有更高膜亲和力和增强效果的两性化合物。
• GLYCO-ENGINEERED INTERLEUKIN-4 BASED ANTAGONISTS
  申请人：Julius-Maximilians-Universität Würzburg

  公开号：EP3553078A1

  公开（公告）日：2019-10-16

  The present invention relates to IL-4 muteins capable of inhibiting IL-4 and/or IL-13 signalling, wherein a non-protein-polymer is conjugated to the mutein via a mutated amino acid, which allows site-directed conjugation of a non-protein polymer. The present invention further relates to nucleic acids and vectors encoding the IL-4 muteins as well as pharmaceutical compositions, kit of parts comprising the IL-4 muteins. The invention further relates to the IL-4 muteins for use in methods of treatment.

  本发明涉及能够抑制IL-4和/或IL-13信号传导的IL-4静音素，其中通过突变氨基酸将非蛋白聚合物与静音素连接，从而实现非蛋白聚合物的定点连接。本发明进一步涉及编码IL-4静音素的核酸和载体，以及包含IL-4静音素的药物组合物、试剂盒。本发明进一步涉及用于治疗方法的IL-4静音素。
• AMPHOTERICIN B CONJUGATED STABILIZED GOLD NANOPARTICLES AND USES THEREOF
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP3834848A1

  公开（公告）日：2021-06-16

  The present invention relates to conjugates of amphotericin B and gold nanoparticles stabilized with thiohexoses or thiopentoses, and a method to produce said nanoparticles. As the conjugates of amphotericin B to the stabilized gold nanoparticles show several advantages over amphotericin B alone, the present invention is also directed to pharmaceutical compositions comprising said nanoparticles, and to their use for treat fungal and leishmanial infection. These amphotericin B stabilized gold nanoparticles are dispersible in water and are not toxic for mammalian cells differently from free amphotericin B and other currently used amphotericin B preparations. Importantly, the conjugates of amphotericin B and stabilized gold nanoparticles are more efficacious in treating all forms of Cryptococcal infections (planktonic, intracellular and biofilms) than amphotericin B. Additionally, the conjugates are more effective against extracellular and intracellular forms of Leishmania mexicana and Leishmania major. Therefore, amphotericin B conjugated to thiohexose or thiopentose stabilized gold nanoparticles offer safer and better treatment option than free amphotericin B, and in particular for Cryptococcal and Leishmanial infections.

  本发明涉及两性霉素 B 和用硫代己酮或硫代戊酮稳定的金纳米颗粒的共轭物，以及生产所述纳米颗粒的方法。与单独使用两性霉素 B 相比，两性霉素 B 与稳定金纳米颗粒的共轭物显示出多种优势，因此本发明还涉及包含上述纳米颗粒的药物组合物，以及它们在治疗真菌和利什曼病感染方面的用途。这些两性霉素 B 稳定金纳米粒子可在水中分散，与游离两性霉素 B 和其他目前使用的两性霉素 B 制剂不同，对哺乳动物细胞无毒性。重要的是，两性霉素 B 和稳定金纳米粒子的共轭物在治疗各种形式的隐球菌感染（浮游、细胞内和生物膜）方面比两性霉素 B 更有效。因此，与游离两性霉素 B 相比，两性霉素 B 与硫代己糖或硫代戊糖稳定金纳米粒子共轭可提供更安全、更好的治疗选择，尤其是对隐球菌和利什曼菌感染。
• Phase-change nanoparticle
  申请人：NEW PHASE LTD.

  公开号：US10172939B2

  公开（公告）日：2019-01-08

  Apparatus and methods are described for use with a subject suffering from cancer. A nanoparticle (22) includes an inner core (30) that comprises a phase-change material that is configured to absorb latent heat of fusion by undergoing a phase change. An outer layer (32) disposed around the inner core includes a plurality of nano-spheres (34) of at least one metal, and a plurality of molecules (38) of a substance that binds preferentially with cancerous cells relative to non-cancerous cells. The nanoparticle has a volume of at least 65,000 nm3 and is elongatable into an ellipsoid, such that, when the nanoparticle is maximally elongated, each of the semi-axes defined by the ellipsoid is greater than 5 nm, and at least two of the semi axes of the ellipsoid are less than 30 nm. Other applications are also described.

  描述了用于癌症患者的仪器和方法。纳米粒子（22）包括内核（30），内核由相变材料组成，该相变材料可通过相变吸收熔融潜热。围绕内核设置的外层（32）包括至少一种金属的多个纳米球体（34）和相对于非癌细胞优先与癌细胞结合的物质的多个分子（38）。纳米粒子的体积至少为 65,000 nm3，可伸长成椭圆形，当纳米粒子最大限度伸长时，椭圆形确定的每个半轴大于 5 nm，椭圆形的至少两个半轴小于 30 nm。还介绍了其他应用。